Research graph
References from Biologic effectiveness increases with earlier biologic initiation after severe asthma onset. Local targets link to admitted publications; unresolved targets remain external evidence.
Asthma
10.1038/nrdp.2015.25 · 2015 · External reference
Unresolved reference
2022 · External reference
Asthma control and disease burden in patients with asthma and allergic comorbidities
10.1080/02770903.2017.1316394 · 2018 · External reference
Asthma costs and social impact
10.1186/s40733-016-0029-3 · 2017 · External reference
Efficacy of biologics in severe, uncontrolled asthma stratified by blood eosinophil count: a systematic review
10.1007/s12325-023-02514-0 · 2023 · External reference
Asthma biologics: comparing trial designs, patient cohorts and study results
10.1016/j.anai.2019.10.016 · 2020 · External reference
Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy
10.1016/j.alit.2022.11.008 · 2023 · External reference
Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: findings from CHRONICLE
10.1016/j.rmed.2023.107285 · 2023 · External reference
Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations
10.1016/j.jaip.2015.05.005 · 2015 · External reference
Biologics and airway remodeling in severe asthma
10.1111/all.15473 · 2022 · External reference
Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study
10.1136/thorax-2021-217032 · 2023 · External reference
The CHRONICLE study of US adults with subspecialist-treated severe asthma: objectives, design, and initial results
2020 · External reference
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
10.1183/09031936.00202013 · 2014 · External reference
Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma
10.1016/j.anai.2023.03.001 · 2023 · External reference
Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment
10.1183/23120541.00211-2024 · 2025 · External reference
Exploring definitions and predictors of response to biologics for severe asthma
10.1016/j.jaip.2024.05.016 · 2024 · External reference
What we know to date about early treatment with biologics in severe asthma: a scoping review about the use of biologics in severe asthma and possible parallels with early rheumatoid arthritis
2025 · External reference
Tezepelumab can restore normal lung function in patients with severe, uncontrolled asthma: pooled results from the PATHWAY and NAVIGATOR studies
10.1007/s41030-025-00294-2 · 2025 · External reference
Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults
10.1164/rccm.202311-2192oc · 2024 · External reference
The status of asthma in the United States
10.5888/pcd21.240005 · 2024 · External reference
Impact of the COVID-19 pandemic on incidence of asthma exacerbations and hospitalizations in US subspecialist-treated patients with severe asthma: results from the CHRONICLE study
10.2147/jaa.s363217 · 2022 · External reference
Reduced effectiveness of anti-IgE treatment among adults with severe asthma with older age of asthma onset: results from the CHRONICLE study
10.2147/jaa.s476774 · 2024 · External reference
